Form 4: Kathleen Sebelius, Humacyte Director, Acquires 50,000 Shares of Common Stock

Director Kathleen Sebelius reports purchasing 50,000 shares of Humacyte, Inc. common stock at $1.32 per share on April 8, 2025.

Summary

• On April 8, 2025, Kathleen Sebelius, a director of Humacyte, Inc. (HUMA), acquired 50,000 shares of common stock.
• The purchase price was $1.32 per share.
• Following the transaction, Ms. Sebelius directly owns 91,207 shares of Humacyte common stock.

Sentiment

Score: 6

Explanation: A director purchasing shares is generally a mildly positive signal, suggesting confidence in the company's future. However, the impact is limited without further context.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director stock purchases are common and closely watched by investors for signals about a company's prospects. This purchase could be interpreted as a positive sign, but should be considered alongside other company news and financial data.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive sign.

Key Dates

Keywords

Humacyte, HUMA, Kathleen Sebelius, Director, Stock Purchase, Form 4, Beneficial Ownership, Common Stock